On June 9, 2011, the China Association of Automobile Manufacturers released the latest domestic automobile production and sales data for the first half of 2011. According to statistics, in June 2011, the national automobile production and sales volume increased slightly compared to the same period of last year, and the growth rate of passenger vehicles was faster, but the performance of commercial vehicles remained low. In the first six months of 2011, automobile production and sales increased by 2.48% and 3.35% year-on-year, which represented a slight decrease from the previous May.
In the first half of 2011, the country's total production and sales of automobiles reached 9,156,000 units and 9,325,200 units, an increase of 2.48% and 3.35% year-on-year. Among them, the production and sales of passenger cars were 7,049,900 and 7,111,300, an increase of 5.36% and 5.75%; the production and sales of commercial vehicles were 2,111,100 and 2,219,900, a year-on-year decrease of 6.07% and 3.67% respectively.
In the first half of 2011, the production and sales of passenger cars were 180,900 units and 190,900 units, an increase of 9.36% and 12.35% year-on-year; the number of sales and sales of trucks was 1,426,800 units and 1,488,300 units, representing a year-on-year decrease of 2.64% and 0.85%; and the production and sales of semitrailer tractors were 129,900 units. 13.76 million units, a year-on-year decrease of 35.13% and 31.96%; 39,200 vehicles and 40,300 units of non-integrated buses were sold and sold, a year-on-year decrease of 4.49% and 1.19%; trucks and non-integrated vehicles were sold and sold 335,300 units and 357,800 units, a year-on-year decrease of 11.07%. And 7.14%.
In the first half of 2011, the top ten automobile manufacturers in terms of overall sales volume were: SAIC, Dongfeng, FAW, Chang'an, BAIC, Chery, Guangzhou Automobile, JAC, Brilliance and Great Wall, with 1,984,600 and 1,505,300 vehicles respectively sold. 1.205 million, 1.14 million, 785,200, 315,900, 314,200, 280,200, 267,800 and 238,400. Compared with the same period of last year, the sales volume of Changan Automobile and Guangzhou Automobile Co., Ltd. decreased, while other companies maintained steady growth. The growth rate of the Great Wall was even more pronounced. The above-mentioned ten companies sold a total of 8,083,900 vehicles, accounting for 87% of the total sales of automobiles.
In the first half of 2011, the top ten commercial vehicle manufacturers in terms of sales volume were: DFG, Beiqi Foton, Jianghuai, FAW, Jinbei, CNHTC, Jiangling, Chang’an, Shaanxi Auto and Nanqi, which each sold 358,400 vehicles. 352,400, 157,100, 154,700, 121,800, 102,100, 99,800, 78,300, 68,700 and 62,800. Compared with the same period in 2010, sales of FAW, CNHTC and Changan declined more significantly, Beiqi Foton declined slightly, and other companies showed a certain increase. In the first half of 2011, the above-mentioned ten companies sold a total of 1.5566 million commercial vehicles, accounting for 70% of the total commercial vehicle sales.
Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
Tofacitinib is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Tofacitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy, but has yet to be linked to cases of clinically apparent acute liver injury.
Tofacitinib Api,Tofacitinib Cas 540737-29-9,Tofacitinib Citrate Project,Tofacitinib Api Cas 540737-29-9
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com